HomeCompareITI vs JNJ

ITI vs JNJ: Dividend Comparison 2026

ITI yields 27.82% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ITI wins by $86.3K in total portfolio value
10 years
ITI
ITI
● Live price
27.82%
Share price
$7.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$116.6K
Annual income
$14,445.19
Full ITI calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ITI vs JNJ

📍 ITI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITI
Annual income on $10K today (after 15% tax)
$2,364.39/yr
After 10yr DRIP, annual income (after tax)
$12,278.41/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ITI beats the other by $8,292.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITI + JNJ for your $10,000?

ITI: 50%JNJ: 50%
100% JNJ50/50100% ITI
Portfolio after 10yr
$73.4K
Annual income
$9,567.30/yr
Blended yield
13.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ITI
Analyst Ratings
6
Buy
3
Hold
Consensus: Buy
Price Target
$8.33
+15.9% upside vs current
Range: $6.00 — $11.00
Altman Z
3.7
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITI buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITIJNJ
Forward yield27.82%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$116.6K$30.3K
Annual income after 10y$14,445.19$4,689.40
Total dividends collected$77.2K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$8.33$228.73

Year-by-year: ITI vs JNJ ($10,000, DRIP)

YearITI PortfolioITI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$13,482$2,781.64$10,592$272.30+$2.9KITI
2$17,930$3,504.77$11,289$357.73+$6.6KITI
3$23,542$4,356.29$12,123$472.89+$11.4KITI
4$30,535$5,345.45$13,141$629.86+$17.4KITI
5$39,152$6,479.81$14,408$846.81+$24.7KITI
6$49,658$7,764.93$16,021$1,151.60+$33.6KITI
7$62,338$9,204.18$18,122$1,588.22+$44.2KITI
8$77,500$10,798.59$20,930$2,228.20+$56.6KITI
9$95,472$12,546.82$24,792$3,191.91+$70.7KITI
10$116,600$14,445.19$30,274$4,689.40+$86.3KITI

ITI vs JNJ: Complete Analysis 2026

ITIStock

Iteris, Inc. provides intelligent transportation systems technology solutions in North America, Europe, South America, and Asia. The company offers smart mobility infrastructure solutions include traveler information systems, transportation performance measurement software, traffic analytics software, transportation operations software, transportation-related data sets, advanced sensing devices, managed services, traffic engineering services, and mobility consulting services. Its products include ClearGuide, ClearRoute, Commercial Vehicle Operations, BlueArgus, TrafficCarma, Vantage Apex, Vantage Fusion, Vantage Next, VantagePegasus, VantageRadius, Vantage Vector, Velocity, SmartCycle, SmartCycle Bike Indicator, SmartSpan, VersiCam, PedTrax, and P-Series products. The company also sells original equipment manufacturer products for the traffic intersection markets, such as traffic signal controllers and traffic signal equipment cabinets. In addition, it offers traffic management centers design, staffing, and operations services; traffic engineering and mobility consulting services include planning, design, development, and implementation of software and hardware-based ITS systems that integrate sensors, video surveillance, computers, and advanced communications equipment; distributes real-time information about traffic conditions; and surface transportation infrastructure systems implementation, and operation and management. Further, the company provides travel demand forecasting and systems engineering, and identify mitigation measures to reduce traffic congestion; ClearMobility platform; and ClearMobility Cloud that enables mobility data management engine, application programming interface framework, and microservices ecosystem. It serves public transportation agencies, municipalities, commercial entities, government agencies, and other transportation infrastructure providers. The company was founded in 1969 and is headquartered in Austin, Texas.

Full ITI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ITI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITI vs SCHDITI vs JEPIITI vs OITI vs KOITI vs MAINITI vs ABBVITI vs MRKITI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.